Luvixasertib
Based on 7 publication(s) in Google Scholar
CFI-402257 is a highly selective and orally bioavailable TTK/Mps1 inhibitor with an IC50 of 1.7 nM for TTK in vitro. CFI-402257 has anti-cancer activity.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.9600%
- CAS 番号: 1610759-22-2
- 分子式: C28H30N6O3
- 分子量:498.58
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
Cytoskeleton Compound Library
HY-L060
-
Highly Selective Inhibitors Library
HY-L158
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
Protein Kinase Compound Library
HY-L196
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
-
Anti-Aging Compound Library Mini
HY-L034M
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Kinase Inhibitor Library
HY-L009
-
Anti-Cancer Compound Library
HY-L025
-
Clinical Compound Library
HY-L026
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
MedChemExpress（MCE）の使用を引用している文献 Luvixasertib
More
Customer Validation & Images
-
WB
生物活性
IC50: 1.7 nM (TTK in vitro)[1].
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HeLa | IC50 |
116 nM
Compound: 86; CFI-402257
|
Inhibition of MPS1 in human HeLa cells assessed as reduction in spindle assembly checkpoint incubated for 4 hrs by p-histone H3/Hoechst 33342 staining based microscopic analysis
Inhibition of MPS1 in human HeLa cells assessed as reduction in spindle assembly checkpoint incubated for 4 hrs by p-histone H3/Hoechst 33342 staining based microscopic analysis
|
[PMID: 32338514] |
| HT-29 | IC50 |
557 nM
Compound: 86; CFI-402257
|
Antiproliferative activity against human HT-29 cells after 96 hrs by crystal violet staining based assay
Antiproliferative activity against human HT-29 cells after 96 hrs by crystal violet staining based assay
|
[PMID: 32338514] |
CFI-402257 is highly selective to TTK. CFI-402257 is tested against a panel of human kinases at 1 μM and inhibits none of the 262 kinases tested. CFI-402257 is a potent inhibitor of cell growth[1].
CFI-402257 (200 nM, 6 h) causes a massive increase in chromosome missegregations[2].
CFI-402257 (0, 50 or 100 nM) induces a dose-dependent dysregulation of the cell cycle, resulting in an increase in the frequency of cells exhibiting an aneuploid DNA content[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HCT116 cells.
-
Concentration:0 nM, 50 nM, 100 nM, 300 nM, 1000 nM, 3000 nM.
-
Incubation Time:48 hours.
-
Result:Resulted in an increase in the frequency of cells exhibiting an aneuploid DNA content.
-
Cell Line:HCT116 cells.
-
Concentration:0 nM, 50 nM or 100 nM.
-
Incubation Time:8, 16, 24 and 48 hours.
-
Result:CFI-402257-induced aneuploidy was accompanied by a progressive accumulation of apoptotic cells that were detectable as early as 16 h following treatment.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Xenografted MDA-MB-231 human TNBC cells and MDA-MB-468 human TNBC cells in mice[2].
-
Dosage:5, 6 mg/kg.
-
Administration:Oral gavage, daily.
-
Result:Xenografted MDA-MB-231 human TNBC cells: 5 mg/kg, tumor growth inhibition (TGI) = 74%; 6 mg/kg, TGI = 89%.
Xenografted MDA-MB-468 human TNBC cells: 5 mg/kg, tumor growth inhibition (TGI) = 75%; 6 mg/kg, TGI = 94%.
-
Animal Model:PDX model of high-grade serous ovarian cancer[2].
-
Dosage:6.5, 7.5 mg/kg.
-
Administration:Oral gavage, daily.
-
Result:6.5 mg/kg, tumor growth inhibition (TGI) = 61%; 7.5 mg/kg, TGI = 97%.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 1610759-22-2
-
性状 Solid
-
分子量 498.58
-
分子式 C28H30N6O3
-
Color White to off-white
-
SMILES
CC1=CC(C2=C3N=C(OC4=CN=CC=C4)C=C(NC[C@@H]5C[C@@](O)(C)C5)N3N=C2)=CC=C1C(NC6CC6)=O
-
別名
CFI-402257
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
Cancer Discov
Cells Lacking the RB1 Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival. [Abstract]2019 Feb;9(2):230-247. PMID: 30373918
Luvixasertib purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2019 Feb;9(2):230-247. [Abstract]
Western analysis of protein expression in different concentrations of CFI-402257 treatment.
-
Commun Biol
Integrated genomics and comprehensive validation reveal drivers of genomic evolution in esophageal adenocarcinoma. [Abstract]2021 May 24;4(1):617. PMID: 34031527 -
Oncol Rep
Energy‑stress‑mediated activation of AMPK sensitizes MPS1 kinase inhibition in triple‑negative breast cancer. [Abstract]2024 Aug;52(2):101. PMID: 38904203 -
PLoS Genet
Barrier-to-autointegration factor protects against the cGAS-STING response to chromatin bridges. [Abstract]2026 Jun 3;22(6):e1012191. PMID: 42234713 -
Front Oncol
Dual TTK/PLK1 inhibition has potent anticancer activity in TNBC as monotherapy and in combination. [Abstract]2024 Aug 9:14:1447807. PMID: 39184047 -
-
溶剤 & 溶解度
DMSO : 1.67 mg/mL (3.35 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
純度とドキュメンテーション
-
データシート (280 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Liu Y, et al. Discovery of Pyrazolo[1,5-a]pyrimidine TTK Inhibitors: CFI-402257 is a Potent, Selective, Bioavailable Anticancer Agent. ACS Med Chem Lett. 2016 May 6;7(7):671-5. [Content Brief]
[2]. Mason JM, et al. Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer. Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):3127-3132. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0057 mL | 10.0285 mL | 20.0570 mL | 50.1424 mL |
Luvixasertib 関連分類
HY-101340 関連分類
Powered by Bioz